The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (Q34470502)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

based on heuristic

inferred from title

10

object named as

John C Byrd

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

14

object named as

Kristie A Blum

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jeffrey A Jones

3

object named as

Jeffrey A Jones

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

8

object named as

Mitch A Phelps

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Robert A Baiocchi

13

object named as

Robert A Baiocchi

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2

object named as

Ming Poi

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

5

object named as

Kami Maddocks

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Pierluigi Porcu

4

object named as

Pierluigi Porcu

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Beth A Christian

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Joseph M Flynn

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Don M Benson

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lai Wei

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

William A Wegener

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

David M Goldenberg

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

7 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

169

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

701-710

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

CD74: a new candidate target for the immunotherapy of B-cell neoplasms

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13354

21 January 2018

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/BJH.13354

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34470502&oldid=1858787995"